NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PubMatic, Inc. ("PubMatic, Inc." or the "Company") (NASDAQ: PUBM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PubMatic, Inc. investors who were adversely affected by alleged securities fraud between February 27, 2025 and August 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pubmatic-inc ...

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 25, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE:Â CTO). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CTO REALTY GROWTH, INC. (CTO), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE OCTOBER 7, 2025(LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURI ...

Core Viewpoint - Investors in LifeMD, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company's management regarding its competitive position and financial guidance [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that from May 7, 2025, to August 5, 2025, LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the management was reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - The positive statements made by the defendants about LifeMD's business operations and prospects were materially misleading and lacked a reasonable basis during the relevant period [3]. Group 2: Participation Information - Investors who suffered losses in LifeMD, Inc. are encouraged to contact the Law Offices of Howard G. Smith before October 27, 2025, to participate in the ongoing lawsuit [2][4]. - Interested parties can reach out via email, telephone, or visit the law firm's website for more information regarding their legal rights [2][4].

Accessibility StatementSkip Navigation NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or "the Company") (NASDAQ: FTNT) and certain of its officers. Class Definition A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/FTNT. or you may contact P ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. ("RCI" or "the Company") (NASDAQ: RICK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities th ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 28, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Hap ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Cytokinetics, Inc. common stock during the specified Class Period, alleging misleading statements regarding the New Drug Application for aficamten [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Cytokinetics, Inc. and covers stock purchases made between December 27, 2023, and May 6, 2025 [1]. - The lawsuit claims that Cytokinetics made false statements about the expected approval timeline for aficamten, specifically regarding the FDA's approval process and the failure to disclose risks related to the Risk Evaluation and Mitigation Strategy [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting Rosen Law Firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - RCI Hospitality Holdings, Inc. is under investigation for potential securities fraud and unlawful business practices following allegations of bribery involving tax auditors, leading to a significant drop in stock price [1][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of RCI investors regarding possible securities fraud or unlawful business practices by the company and its executives [1]. - The New York Attorney General's office indicted certain top executives of RCI, alleging they bribed an auditor to evade over $8 million in sales taxes from 2010 to 2024 [3]. Group 2: Market Reaction - Following the news of the indictment, RCI's stock price fell by $25.80 per share, representing a decline of 24.83%, closing at $25.80 per share on September 17, 2025 [3].

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Cytokinetics a ...

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging investors of Jasper Therapeutics, Inc. (JSPR) to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking investors who may have been affected by the alleged securities fraud involving Jasper Therapeutics [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications for investors [1] - This action reflects broader issues within the biotechnology sector, where companies may face scrutiny over their financial disclosures and operational transparency [1]